Top Page
Sigma Healthcare Ltd
(Sydney:SIG)
Sigma Healthcare Ltd (SIG) vs. iShares MSCI Australia ETF (EWA)
Sigma Healthcare Ltd Business Overview & Revenue Model
Sigma Healthcare Ltd Financial Statement Overview
| Breakdown | TTM | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.51B | 4.89B | 3.32B | 3.66B | 3.45B | 3.40B |
| Gross Profit | 1.16B | 334.05M | 189.82M | 224.07M | 199.42M | 210.61M |
| EBITDA | 614.50M | 55.47M | 53.25M | 50.20M | 30.23M | 68.96M |
| Net Income | 362.26M | -13.84M | 4.51M | 1.81M | -7.24M | 43.53M |
Balance Sheet | ||||||
| Total Assets | 8.74B | 1.83B | 1.40B | 1.20B | 1.28B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 163.13M | 14.57M | 356.50M | 16.65M | 31.14M | 16.13M |
| Total Debt | 3.04B | 132.09M | 136.63M | 226.99M | 323.43M | 215.23M |
| Total Liabilities | 3.85B | 991.29M | 531.52M | 723.84M | 786.65M | 705.00M |
| Stockholders Equity | 4.90B | 837.86M | 870.77M | 475.92M | 487.19M | 513.67M |
Cash Flow | ||||||
| Free Cash Flow | 80.43M | -323.50M | 37.25M | 113.34M | -60.48M | -64.56M |
| Operating Cash Flow | 109.69M | -315.59M | 41.97M | 142.74M | -46.28M | -13.13M |
| Investing Cash Flow | 31.58M | -1.60M | 5.73M | -28.60M | -16.59M | 124.36M |
| Financing Cash Flow | -339.17M | -24.73M | 295.82M | -116.94M | 128.89M | -265.71M |
Sigma Healthcare Ltd Technical Analysis
Sigma Healthcare Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$11.79B | 21.51 | 6.32% | 4.69% | 9.44% | -0.37% | |
59 Neutral | AU$426.65M | 16.69 | 18.59% | 4.60% | 6.73% | 37.16% | |
56 Neutral | AU$2.11B | 55.07 | ― | 2.30% | 14.61% | ― | |
54 Neutral | AU$9.91B | 36.29 | 0.38% | 2.25% | 6.82% | -99.27% | |
53 Neutral | €31.58B | 56.13 | ― | 0.44% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €486.51M | -0.89 | -67.21% | ― | -23.02% | 33.11% |
Sigma Healthcare Ltd Corporate Events
Sigma Healthcare has declared an ordinary interim dividend of A$0.02 per fully paid share, relating to the six‑month period ending 31 December 2025. The dividend will trade ex‑dividend on 4 March 2026, with a record date of 5 March and payment scheduled for 20 March, signalling ongoing cash returns to shareholders and reflecting the company’s current capital management stance.
The announcement confirms the payout is tied to Sigma’s half‑year performance and follows the standard timetable for ASX‑listed distributions. While no additional approvals were noted as required, the move underlines management’s confidence in the company’s ability to generate distributable earnings and may be seen as supportive for investor income expectations in the healthcare distribution space.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.20 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare reported robust first-half 2026 results, with revenue rising 14.9% to $5.5 billion, normalised EBIT up 18.7% to $582.9 million and normalised NPAT up 19.2% to $392.0 million, underpinned by strong Chemist Warehouse store sales and growing international operations. Australian Chemist Warehouse branded sales climbed 17.2% to $5.1 billion, supported by like-for-like growth of 15.0%, an expanding store network, increased GLP-1 medicine sales and the shift to fulfilling online orders from stores.
Management is also reinvigorating the Amcal and Discount Drug Stores brands, completing the conversion of MyChemist franchise stores and planning additional Amcal openings, while expanding its portfolio of owned and exclusive label products, led by Wagner generics. International retail network sales grew 24.5% to more than $807 million, with rapid store rollout in New Zealand and Ireland, where a new distribution centre is improving operational capability and underlining the transferability of the Chemist Warehouse model.
Supply-chain scale is delivering efficiencies, as a 5.1% increase in units distributed was achieved with only a 0.3% rise in warehouse and distribution costs, helping lift normalised EBIT margin by 34 basis points and earnings per share by 19.4%. Integration of the merged group is progressing to plan, with $13 million in early synergies, a strong balance sheet featuring net debt of $635.1 million at just 0.6 times normalised EBITDA, and an interim fully franked dividend of 2.0 cents per share reflecting robust cash generation.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare, now reporting as a merged group with Chemist Warehouse, has aligned its financial year with Chemist Warehouse’s 30 June year-end following ASIC relief and corresponding ASX confirmations. The reverse acquisition accounting means prior-period comparatives reflect Chemist Warehouse only, reshaping how investors interpret the group’s historical performance and scale.
For the half year to 31 December 2025, the merged group posted sales of $5.51 billion, up 180.5% on the prior corresponding period, and net profit after tax of $379.1 million, an increase of 23.1%. Despite stronger earnings, net tangible asset backing per share fell sharply to 9.0 cents, while the board declared a fully franked interim dividend of 2.0 cents per share for the year ending 30 June 2026, signalling an ongoing commitment to shareholder returns.
The group reported no gains or losses of control over material entities during the period and has no dividend reinvestment plan in place. The reviewed half-year accounts, signed off without modification by PwC, provide the first comprehensive snapshot of the combined Sigma–Chemist Warehouse business and will serve as the baseline for future market disclosures.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare has notified the market of the issue of 2,403,962 unquoted performance rights under its employee incentive scheme, effective 9 January 2026. The new grants, which are not intended to be quoted on the ASX, form part of Sigma’s broader approach to staff remuneration and retention, aligning employee rewards with company performance and potentially impacting future equity dilution for existing shareholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare has disclosed a change in the interests of director Mario Verrocchi, who has been granted 314,021 rights to acquire fully paid ordinary shares under the company’s 2025 Long Term Incentive Plan, approved at its 2025 annual general meeting. The performance rights, issued for nil consideration as part of Verrocchi’s remuneration package, increase his direct holdings to include these 2025 LTI rights in addition to his existing substantial direct and indirect shareholdings, underscoring Sigma’s continued use of equity-based incentives to align executive interests with those of shareholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare has disclosed a change in director Danielle Di Pilla’s interests following the grant of 141,591 performance rights under the company’s 2025 Long Term Incentive Plan. The rights, issued for nil consideration as part of her employee incentive package and approved at the 2025 AGM, increase Di Pilla’s direct holdings to include both her substantial existing shareholding and the new long-term incentive rights, while her indirect interests via the Di Pilla Family Trust remain unchanged, underscoring Sigma’s continued use of equity-based remuneration to align executive interests with shareholder value.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare has disclosed a change in the equity interests of its director and chief executive, Vikesh Ramsunder, following the allocation of new performance rights under its long-term incentive framework. The grant, made for nil consideration as part of the company’s 2025 Long Term Incentive Plan approved at the 2025 AGM, adds 813,449 rights to acquire fully paid ordinary shares to Ramsunder’s existing holdings, underscoring Sigma’s continued use of equity-based remuneration to align executive incentives with shareholder value and long-term performance.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare has advised that it will publish its FY26 half-year financial results for the period ending 31 December 2025 to the ASX on the morning of Thursday, 26 February 2026. The company will follow the release with an investor webcast presentation at 10:00am AEDT on the same day, with access details to be provided closer to the date and made available via its investor relations website, signalling its ongoing engagement with investors and the market ahead of the interim results.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.39 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.